Moderna: Shares Plunge Over 25% After Apparent Leak of Phase 3 Melanoma Cancer Vaccine Data

$MRNA (+3,5%)

⠀

• Reportedly leaked results show Moderna and Merck's $MRK personalized mRNA vaccine plus Keytruda reduced melanoma recurrence or death risk by 42% versus Keytruda alone.

• At two years, 82.2% of combination-treated patients remained alive and cancer-free versus 70% on Keytruda alone.

• Phase 3 trial enrolled 1,137 patients. Data reportedly appeared briefly on Oncology Central ahead of Saturday's planned ESMO presentation. Results remain unconfirmed.